NTRK1 and neoplasm: NTRK gene fusion positive tumours have also provided successful examples of novel targeted therapies in the clinical setting, with substantial and durable responses documented for first generation TRK inhibitors, which led to FDA and EMA approvals of larotrectinib and entrectinib for patients at an advanced stage [26].